Farringdon Capital’s Elevance Health ELV Stock Holding History

Farringdon Capital’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-839	Closed	-$310K	–	422
2024 Q4	$310K	Buy	+839	New	+$351K	0.13%	270

Other funds holding ELV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Farringdon Capital's ELV Position: Q1 2025 in Review

Farringdon Capital sold out of Elevance Health (ELV) in Q1 2025, closing a stake of 839 shares — an estimated $310K sold.

Farringdon Capital first reported a position in ELV in Q4 2024 and held it in 1 quarter. The position peaked at $310K in Q4 2024. 1,661 funds tracked by Wall St. Rank hold ELV as of Q1 2025.

Farringdon Capital reported no remaining Elevance Health position as of Q1 2025 after selling out during the quarter.
Farringdon Capital sold 839 Elevance Health shares in Q1 2025, an estimated $310K.
Farringdon Capital first reported a position in Elevance Health in Q4 2024 and held it in 1 quarter.
Farringdon Capital's Elevance Health position peaked at $310K in Q4 2024.
1,661 funds tracked by Wall St. Rank held Elevance Health as of Q1 2025.

Based on Farringdon Capital's 13F filing for Q1 2025, filed 15 May 2025.